Recurrent anal fistulae: Limited surgery supported by stem cells

Table 3 Outcomes of published clinical experience of stem cell treatment for anal fistula

Ref.	Procedure	No. of patients treated	Healed (n)	Follow-up (mo)	Recurrence (n)	SAE (n)
García-Olmo et al[11]	Closure of IO. Injection in site, without fibrin glue	1	1	3	0	0
García-Olmo et al[12]	Cells resuspended in fibrin glue. Injection in site	9	6	12	Not specified	0
García-Olmo et al[13]	Closure of IO. Injection in site	Fibrin glue: 25 Fibrin glue + eASC: 24	Fibrin glue: 3 Fibrin glue + eASC: 17	12	Fibrin glue: 0 Fibrin glue + eASC: 2	4 (1 related to fibrin glue, others unrelated)
García-Olmo et al[22]	Closure of IO. Injection in site, without fibrin glue	1	1	36	1	0
Ciccocioppo et al[25]	Four injections in site	10	7	12	0	0
Cho et al[24]	Closure of IO and fibrin glue. Injection in site	9	3	15	0	0
Herreros et al[14]	Closure of IO. Injection in site	eASC: 64 Fibrin glue + eASC: 60 Fibrin glue: 59	eASC: 27 Fibrin glue + eASC: 24 Fibrin glue: 23	6	eASC: 0 Fibrin glue + eASC: 4 Fibrin glue: 0	4 unrelated to study treatment
Herreros et al[14]	Closure of IO. Injection in site	Not specified	eASC: 57% Fibrin glue+ eASC: 52.4% Fibrin glue: 37.3%	12	Not specified	1 unrelated to study treatment
Guadalajara et al[23]	Closure of IO. Injection in site	Fibrin glue: 13 Fibrin glue + eASC: 21	Fibrin glue: 3 Fibrin glue + eASC: 10	38	Fibrin glue: 1 Fibrin glue + eASC: 5	0
de la Portilla et al[17]	Closure of IO. Injection in site, without fibrin glue	24	9	4	Not specified	2 unrelated to study treatment
Lee et al[20]	Injection in site and fibrin glue	43	27	12	4	0

IO: Internal opening; SAE: Serious adverse events (those requiring hospital admission > 24 h); eASC: Expanded adult stem cells.